Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · STANDARD BIOTOOLS INC. (LAB)

Standard BioTools agrees to sell Microfluidics business to ARCHIMED

Neutral Impact 3 of 5 m&a Written later

Standard BioTools said it has signed a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on healthcare. The sale is expected to close in approximately 30 days, subject to customary closing conditions, and the business will keep operating as part of the company until then. The filing does not disclose the purchase price or the financial effect of the sale on the company.

Key points

  • Definitive agreement announced October 5, 2026, with ARCHIMED, a healthcare-focused investment firm
  • Closing expected in approximately 30 days, subject to customary closing conditions
  • Microfluidics business continues to operate within Standard BioTools until closing
  • The filing does not disclose the sale price or financial impact

The filing

CompanySTANDARD BIOTOOLS INC. (LAB)
Form8-K, current report
Filed with the SECOct 5, 2026, 4:16 PM ET
Accession number0001140361-26-038624

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.